Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis.

Fetal diagnosis and therapy - 1 Jan 2023

Gómez-Montes Enery, Salcedo Lobato Enrique, Galindo Izquierdo Alberto, García Alcázar Diana, Villalain González Cecilia, Moral-Pumarega Maria Teresa, Bustos Lozano Gerardo, Luna-Paredes Carmen

Abstract excerpt

INTRODUCTION: Cystic fibrosis (CF) is a potentially severe disease. The development of new therapies with cystic fibrosis transmembrane conductance regulator (CFTR) modulators has been a great advance in the management of this condition because they improve the function of the faulty CFTR protein rather than palliate its consequences. CFTR modulator therapy improves pancreatic and lung function and, therefore,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Infant, Newborn

Share to Mutation

Share to Pregnancy

Share to Quality of Life

Source

Identifiers

PMID: 36996799
DOI: 10.1159/000530261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis.PMID 36996799Read ↗

A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus.Semantic proximity Read ↗

CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: Insights from an unsuccessful caseSemantic proximity Read ↗

Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?Semantic proximity Read ↗

"Shifting sands in cystic fibrosis": impacts of CFTR modulators on reproductive health in people with cystic fibrosis and challenges related to in utero exposure.Semantic proximity Read ↗

Pregnancy in cystic fibrosis: Review of the literature and expert recommendationsSemantic proximity Read ↗

Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancySemantic proximity Read ↗

Pregnancy in Cystic Fibrosis: Review of the Literature and Expert RecommendationsSemantic proximity Read ↗

CFTR modulators and pregnancy: A Case ReportSemantic proximity Read ↗

Use of CFTR modulators in special populations, part 1: Pregnancy and lactation.Semantic proximity Read ↗

CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic FibrosisSemantic proximity Read ↗

Meconium ileus in newborns with cystic fibrosis - results of treatment in the group of patients operated on in the years 2000-2014.Semantic proximity Read ↗

Effects of modulator therapies on endocrine complications in adults with cystic fibrosis: a narrative review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.